Podcast appearances and mentions of gerard silvestri

Host: Gerard A. Silvestri MD, MS, Master FCCP Guest: Anurag Singh, MD Guest: Adam H. Fox, MD, MSc Guest: Mariam Alexander, MD, PhD Despite the typically poor prognosis of extensive-stage small cell lung cancer, recent advancements are reshaping clinical perspectives on treatment. New and emerging options show promise for prolonged survival and improved quality of life. Join Drs. Gerard Silvestri, Adam Fox, Mariam Alexander, and Anurag Singh as they discuss how the therapeutic landscape is evolving for these patients. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina. Dr. Fox is a pulmonologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Alexander is a medical oncologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Singh is a Professor of Radiation Oncology and the Director of Radiation Research at the Roswell Park Cancer Center in New York. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Host: Gerard A. Silvestri MD, MS, Master FCCP Guest: Anurag Singh, MD Guest: Adam H. Fox, MD, MSc Guest: Mariam Alexander, MD, PhD Recent therapeutic advances are reshaping our approach to limited-stage small cell lung cancer. In this multidisciplinary discussion, Dr. Gerard Silvestri sits down with Drs. Adam Fox, Mariam Alexander, and Anurag Singh to explore the evolving standard of care and practical considerations for timely and effective care. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina. Dr. Fox is a pulmonologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Alexander is a medical oncologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Singh is a Professor of Radiation Oncology and the Director of Radiation Research at the Roswell Park Cancer Center in New York. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

*This episode was originally part of the ACR Bulletin podcast and was recorded in 2020. In the final part of their five-part conversation, Dr. Debra Dyer, MD, and Dr. Gerard Silvestri, MD, showcase the National Lung Cancer Roundtable's (NLCRT) work with member organizations to advance efforts to promote lung cancer screening. As part of National Lung Cancer Awareness Month 2020, Dr. Debra Dyer, Chair of the ACR's Lung Cancer Screening Steering Committee, had a series of conversations with stakeholders across the healthcare spectrum about myths in lung screening in the limited series “Mythbusting Lung Cancer Screening.” Dr. Gerard Silvestri is a lung cancer pulmonologist at the Medical University of South Carolina. He has served on the Data and Safety Monitoring Board of the national Prostate, Lung, Colorectal and Ovarian screening trial, representing the lung arm of the trial. Dr. Silvestri participates as a Steering Committee member and Task Group Chair on the American Cancer Society's National Lung Cancer Screening Roundtable Steering Committee. Additional information on this topic, as well as the resources mentioned during the episode, can be found at https://www.acr.org/Clinical-Resources/Lung-Cancer-Screening-Resources.

*This episode was originally part of the ACR Bulletin podcast and was recorded in 2020. To get the pulmonologist perspective of lung cancer screening, Dr. Debra Dyer, MD, speaks with Dr. Gerard Silvestri, MD, about what the role of the pulmonologist is in lung cancer screening in the first episode of this five-part conversation. As part of National Lung Cancer Awareness Month 2020, Dr. Debra Dyer, Chair of the ACR's Lung Cancer Screening Steering Committee, had a series of conversations with stakeholders across the healthcare spectrum about myths in lung screening in the limited series “Mythbusting Lung Cancer Screening.” Dr. Gerard Silvestri is a lung cancer pulmonologist at the Medical University of South Carolina. He has served on the Data and Safety Monitoring Board of the national Prostate, Lung, Colorectal and Ovarian screening trial, representing the lung arm of the trial. Dr. Silvestri participates as a Steering Committee member and Task Group Chair on the American Cancer Society's National Lung Cancer Screening Roundtable Steering Committee. Additional information on this topic, as well as the resources mentioned during the episode, can be found at https://www.acr.org/Clinical-Resources/Lung-Cancer-Screening-Resources.

*This episode was originally part of the ACR Bulletin podcast and was recorded in 2020. Dr. Debra Dyer, MD, continues her conversation with Dr. Gerard Silvestri, MD, about what a patient can expect regarding tobacco treatment in the context of lung cancer screening in part two of this five-part conversation. As part of National Lung Cancer Awareness Month 2020, Dr. Debra Dyer, Chair of the ACR's Lung Cancer Screening Steering Committee, had a series of conversations with stakeholders across the healthcare spectrum about myths in lung screening in the limited series “Mythbusting Lung Cancer Screening.” Dr. Gerard Silvestri is a lung cancer pulmonologist at the Medical University of South Carolina. He has served on the Data and Safety Monitoring Board of the national Prostate, Lung, Colorectal and Ovarian screening trial, representing the lung arm of the trial. Dr. Silvestri participates as a Steering Committee member and Task Group Chair on the American Cancer Society's National Lung Cancer Screening Roundtable Steering Committee. Additional information on this topic, as well as the resources mentioned during the episode, can be found at https://www.acr.org/Clinical-Resources/Lung-Cancer-Screening-Resources.

*This episode was originally part of the ACR Bulletin podcast and was recorded in 2020. In part three of their five-part conversation, Dr. Debra Dyer, MD, and Dr. Gerard Silvestri, MD, discuss what a patient should expect if their lung cancer screening CT exam is abnormal. As part of National Lung Cancer Awareness Month 2020, Dr. Debra Dyer, Chair of the ACR's Lung Cancer Screening Steering Committee, had a series of conversations with stakeholders across the healthcare spectrum about myths in lung screening in the limited series “Mythbusting Lung Cancer Screening.” Dr. Gerard Silvestri is a lung cancer pulmonologist at the Medical University of South Carolina. He has served on the Data and Safety Monitoring Board of the national Prostate, Lung, Colorectal and Ovarian screening trial, representing the lung arm of the trial. Dr. Silvestri participates as a Steering Committee member and Task Group Chair on the American Cancer Society's National Lung Cancer Screening Roundtable Steering Committee. Additional information on this topic, as well as the resources mentioned during the episode, can be found at https://www.acr.org/Clinical-Resources/Lung-Cancer-Screening-Resources.

*This episode was originally part of the ACR Bulletin podcast and was recorded in 2020. Dr. Debra Dyer, MD, continues her conversation with Dr. Gerard Silvestri, MD, about the importance of adhering to the screening protocol annually to achieve full benefit in the fourth installment in their five-part discussion. As part of National Lung Cancer Awareness Month 2020, Dr. Debra Dyer, Chair of the ACR's Lung Cancer Screening Steering Committee, had a series of conversations with stakeholders across the healthcare spectrum about myths in lung screening in the limited series “Mythbusting Lung Cancer Screening.” Dr. Gerard Silvestri is a lung cancer pulmonologist at the Medical University of South Carolina. He has served on the Data and Safety Monitoring Board of the national Prostate, Lung, Colorectal and Ovarian screening trial, representing the lung arm of the trial. Dr. Silvestri participates as a Steering Committee member and Task Group Chair on the American Cancer Society's National Lung Cancer Screening Roundtable Steering Committee. Additional information on this topic, as well as the resources mentioned during the episode, can be found at https://www.acr.org/Clinical-Resources/Lung-Cancer-Screening-Resources.

Join moderators Alice Gallo de Moraes, MD, and Vineesha Arelli, MD, and journal CHEST® authors Peter Mazzone, MD, MPH, FCCP, and Gerard Silvestri, MD, MS, as they discuss the article, "Screening for Lung Cancer: CHEST Guideline and Expert Panel Report – Executive Summary," which was published in the September issue. DOI: https://doi.org/10.1016/j.chest.2021.06.063

On a special episode, Tradeoffs host Dan Gorenstein talks with a host of experts about screening for lung cancer, America's number one cancer killer. While CT scans have provided early insights into a cancer that previously wasn't caught until far too late, this tool has also led to unnecessary procedures, costs, and even disability and death for patients that may not have even been sick. You'll hear from pulmonologist Dr. Gerard Silvestri; behavioral scientist and nurse practitioner Dr. Lisa Carter-Harris; Dr. Cherie Erkmen, surgeon and director of Temple University's Lung Cancer Screening Program; Johns Hopkins oncologist Dr. Otis Brawley; Ida Pittman, a lung cancer patient, and Helena Price, her cousin and health care advocate. If you like this episode, check out the Tradeoffs' podcast www.tradeoffs.org

Host: Gerard A. Silvestri MD, MS, FCCP Guest: Michael S. Machuzak, MD Clinicians can uncover a wealth of information from a non-small cell lung cancer patient's collected tissue that can help inform treatment decisions. To dive into this idea further, Dr. Gerard Silvestri is joined by his colleague Dr. Michael Machuzak, Full Staff Member in the Department of Pulmonary, Allergy, and Critical Care Medicine at Cleveland Clinic. Together they review the importance of tissue acquisition, proper handling of specimens, rapid onsite evaluation during EBUS-TBNA procedures, and much more.An educational campaign brought to you by CHEST, in collaboration with AstraZeneca.

Host: Gerard A. Silvestri MD, MS, FCCP Guest: Lynn Tanoue, MD, MBA About 10 percent of all cancer patients develop treatment-related pulmonary complications, and for lung cancer patients, that risk is even greater. Dr. Gerard Silvestri sits down with Dr. Lynn Tanoue, Professor of Medicine and Vice Chair of Clinical Affairs in the section of pulmonary critical care and sleep medicine at the Yale Cancer Center in New Haven, Connecticut, to discuss pulmonary toxicities related to lung cancer treatment.An educational campaign brought to you by CHEST, in collaboration with AstraZeneca.

"I think we need to step back first before we even ask the policy question and ask this simple question, is it okay in the United States to die of cancer simply because you don't have health insurance?" - Dr. Gerard SilvestriCancer is a leading cause of death in the United States. Although there have been declines in cancer deaths in recent years, improvements have not been equally distributed across the population.The risk of cancer increases with age and nearly a quarter of all new cancers diagnosed each year in the US occur among those aged 55 to 64 years old. At age 65, most Americans gain Medicare coverage, creating a ready comparison of cancer outcomes between those just below age 65 — who may have private insurance, Medicaid, or are uninsured — and those above 65 who are on Medicare.The relationship between insurance coverage and cancer outcomes is the subject of this episode of A Health Podyssey.  Dr. Gerard Silvestri, a professor of thoracic oncology at the Medical University of South Carolina, joins the program to discuss a paper he and co-authors published in the May 2021 issue of Health Affairs wherein they found significantly worse survival rates for uninsured patients ages 60 to 64 in comparison to Medicare beneficiaries.Listen to Alan Weil interview Gerard Silvestri on cancer outcomes among Medicare beneficiaries and their younger, uninsured counterparts.Subscribe: RSS | Apple Podcasts | Spotify | Stitcher | Google Podcasts

Debra Dyer, MD, Chair of the Lung Cancer Screening Steering committee has a conversation with Dr. Gerard Silvestri about what the role of the pulmonologist is in lung cancer screening.

Debra Dyer, MD, Chair of the Lung Cancer Screening Steering committee has a conversation with Gerard Silvestri, MD about what a patient can expect regarding tobacco treatment in the context of lung cancer screening.

Debra Dyer, MD, Chair of the Lung Cancer Screening Steering committee has a conversation with Dr. Gerard Silvestri, MD about what a patient should expect if their lung cancer screening CT exam is abnormal.

Debra Dyer, MD, Chair of the Lung Cancer Screening Steering committee has a conversation with Dr. Gerard Silvestri about the importance of adhering to the screening protocol annually in order to achieve full benefit.

Debra Dyer, MD, Chair of the Lung Cancer Screening Steering committee has a conversation with Dr. Gerard Silvestri about the National Lung Cancer Roundtables work with member organizations to advance efforts to promote lung cancer screening.

As a lung cancer pulmonologist who sees 5-7 new patients every week, runs a patient-focused clinical research program, and has been helping patients fight lung cancer for more than 25 years, Gerard Silvestri, MD, MS, has a long history with this disease. So when he says, “I have never been in my career so optimistic as I am now,” take note. In this interview Dr. Silvestri talks about reasons for optimism in nearly every aspect of lung cancer research, from prevention and screening to new treatments and survivorship. Dr. Silvestri is Professor of Medicine and the George C. and Margaret M. Hillenbrand Endowed Chair at the Medical University of South Carolina. He’s also on the steering committee of the National Lung Cancer Roundtable, a coalition of leading professional, government and non-governmental organizations working to accelerate the nation's efforts to reduce mortality from lung cancer. 2:29 – On his work in the clinic and the lab: “Every Tuesday I see between 5 and 7 new patients with lumps and bumps, and my job is to do three things—ask the questions: ‘What is it?’ (that’s the diagnosis); ‘Where is it?’ (that’s the stage); and ‘What can we do about it?’ (those are the treatment options).” 4:21 – What should people know about lung cancer? After noting that, “more women will die of lung cancer than all other female cancers combined,” he shared encouraging news about prevention and screening. 6:36 – On what it means to be a high-risk patient 8:42 – On where high-risk patients should go for screening, and the importance of returning for follow-up screenings: “The where is actually really important…you should be in a place that can really care for you.” 12:11 – On lung cancer in patients who have never smoked 15:09 – On why he’s never been more optimistic about treatment breakthroughs 20:04 – On the work of the National Lung Cancer Roundtable 23:30 – On three aspects of the Roundtable’s work that are particularly exciting 27:51 – A message he’d like to share with cancer patients and caregivers

Dr. Gerard Silvestri, Medical University of South Carolina, describes the steps necessary to work up a lung cancer diagnosis, from initial scan to choice of treatment.

Dr. Gerard Silvestri, Medical University of South Carolina, describes the steps necessary to work up a lung cancer diagnosis, from initial scan to choice of treatment.

Dr. Gerard Silvestri, Medical University of South Carolina, describes the steps necessary to work up a lung cancer diagnosis, from initial scan to choice of treatment.

Dr. Gerard Silvestri, Medical University of South Carolina, defines pulmonary function testing, and describes how lung cancer surgeons use them.

Dr. Gerard Silvestri, Medical University of South Carolina, defines pulmonary function testing, and describes how lung cancer surgeons use them.

Dr. Gerard Silvestri, Medical University of South Carolina, defines pulmonary function testing, and describes how lung cancer surgeons use them.

Dr. Gerard Silvestri, Medical University of South Carolina, discusses the use of PET scans in lung cancer workup.

Dr. Gerard Silvestri, Medical University of South Carolina, discusses the use of PET scans in lung cancer workup.

Dr. Gerard Silvestri, Medical University of South Carolina, discusses the use of PET scans in lung cancer workup.

Dr. Gerard Silvestri, Medical University of South Carolina, describes several procedures used to obtain biopsy tissue in order to diagnose lung cancer.

Dr. Gerard Silvestri, Medical University of South Carolina, describes several procedures used to obtain biopsy tissue in order to diagnose lung cancer.

Dr. Gerard Silvestri, Medical University of South Carolina, describes several procedures used to obtain biopsy tissue in order to diagnose lung cancer.

Dr. Gerard Silvestri, Medical University of South Carolina, discusses the benefits and drawbacks of lung cancer screenings.

Dr. Gerard Silvestri, Medical University of South Carolina, discusses the benefits and drawbacks of lung cancer screenings.

Dr. Gerard Silvestri, Medical University of South Carolina, discusses the benefits and drawbacks of lung cancer screenings.

Dr. Gerard Silvestri, Medical University of South Carolina, describes some of the typical presenting symptoms of lung cancer.

Dr. Gerard Silvestri, Medical University of South Carolina, describes some of the typical presenting symptoms of lung cancer.

Dr. Gerard Silvestri, Medical University of South Carolina, describes some of the typical presenting symptoms of lung cancer.

Dr. Gerard Silvestri, pulmonologist from Medical University of South Carolina (MUSC) in Charleston, reviews the subject of pneumonitis (inflamation of the lung tissue) induced by EGFR inhibitors or chest radiation.

Dr. Gerard Silvestri, pulmonologist from Medical University of South Carolina (MUSC) in Charleston, reviews the subject of pneumonitis (inflamation of the lung tissue) induced by EGFR inhibitors or chest radiation.

Dr. Gerard Silvestri, pulmonologist from Medical University of South Carolina (MUSC) in Charleston, reviews the subject of pneumonitis (inflamation of the lung tissue) induced by chemotherapy commonly used for treating lung cancer.

Dr. Gerard Silvestri, pulmonologist from Medical University of South Carolina (MUSC) in Charleston, reviews the subject of pneumonitis (inflamation of the lung tissue) induced by chemotherapy commonly used for treating lung cancer.

This slide presentation by Dr. Gerard Silvestri, pulmonologist at Medical Univ. of South Carolina, covers the key methods of evaluating a new lung cancer, including initial diagnosis and staging studies.